Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 90 of 1298 for:    survival | Neuroendocrine Tumors

Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs (MetNET1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02294006
Recruitment Status : Unknown
Verified November 2014 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Recruitment status was:  Recruiting
First Posted : November 19, 2014
Last Update Posted : November 19, 2014
Sponsor:
Information provided by (Responsible Party):
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:

Abnormal PI3K-Akt-mTOR (mammalian target of rapamycin) pathway signaling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor 1 (IGF1), has been implicated in the proliferation of pNET ( primitive neuroectodermal tumor) cells. Everolimus ,an mTOR inhibitor (a central regulator of growth/proliferation, cellular metabolism and angiogenesis) has shown antitumor benefit in pNETs alone and in combination with Octreotide LAR in RADIANT-1 and RADIANT-3 studies.

Despite EVE-based phase II/III trials improve progression-free survival (PFS) for pNETs, they are limited to significantly prolong overall survival (OS). Metformin has recently shown some anti-cancer activity, both in vitro and in vivo studies by antisecretory properties to decrease insulin and IGF1 levels; and by antitumor effect due to AMPK (adenosine monophosphate kinase) activation and consequently inhibition to TSC1(tuberous sclerosis complex 1) -2/mTOR complex, mediated to LKB1 oncogene expression. The investigators retrospective experience, despite in a limited group of pWDNET, highlights the role of MET to improve clinical benefit in diabetic pts receiving EVE-OCT (octreotide) combination.

This study will investigate the antiproliferative potential of MET in combination with EVE and OCT in pWDNETs. MetNET1 prospective trial (EudraCT 2014-000888-41) may be helpful to either confirm or discard these preliminary findings.

The main objective of this study is to evaluate progression free survival rate at 12 months of treatment. The secondary objectives are safety, overall survival, response rate evaluation.

A sub-study analysis will evaluate circulant biomarkers levels (IL 6, IGF1) in blood samples.


Condition or disease Intervention/treatment Phase
Well Differentiated Pancreatic Endocrine Tumor Drug: Everolimus plus Octreotide LAR plus Metformin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study
Study Start Date : June 2014
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017


Arm Intervention/treatment
Experimental: everolimus+octreotide LAR+metformin Drug: Everolimus plus Octreotide LAR plus Metformin



Primary Outcome Measures :
  1. to determine the progression free survival rate (PFS) at 12 months from the first drug administration in patients with advanced pancreatic neuroendocrine tumors [ Time Frame: 1 year ]
    progression free survival rate at 12th month of treatment, according to RECIST criteria version 1.0


Secondary Outcome Measures :
  1. to determine the safety and tolerability of the combination of Everolimus, Octreotide LAR and Metformin as measured according to the National cancer Institute-Common Toxicity Criteria v. 3.0 guidelines [ Time Frame: 1 year ]
    safety is measured according to the National cancer Institute-Common Toxicity Criteria v. 3.0 guidelines

  2. to determine the overall survival of the combination of Everolimus, Octreotide LAR and Metformin. [ Time Frame: 3 years ]
    overall survival is defined as the time interval between enrollment and the date of the death from any cause.

  3. to determine the response rate of the combination of Everolimus, Octreotide LAR and Metformin. [ Time Frame: 1 year ]
    response rate is defined as the percentage of patients presenting objective responce of the disease, according to RECIST Criteria version 1.0.

  4. to determine the biochemical response of the combination of Everolimus, Octreotide LAR and Metformin. [ Time Frame: 1 year ]
    the biochemical response is defined as the impact of study treatment on general neuroendocrine tumors biomarkers, Chromogranine A and Enolase neuron specific and circulating plasma IL6, IL8 and IGF-1 levels.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signature of written informed consent (approved by the Institutional Ethics Committee Independent ) obtained after a careful study of screening procedures
  2. Age >= 18 years old.
  3. Patients with histological evidence of pNET well-differentiated G1 -G2
  4. Configurable tumor disease (according to RECIST (Response Evaluation Criteria In Solid Tumors) ) .
  5. Karnofsky Performance Status >= 60%.
  6. Life expectancy greater than 6 months.
  7. Is permitted to enroll patients who have not received any treatment for advanced disease or patients pretreated with surgery , chemotherapy or somatostatin analogues .
  8. Basal blood tests :

    • Counts of neutrophils in absolute value > 1.5 x 109 / L.
    • Platelet count > 100 x 109 / L.
    • Hemoglobin > 9 g / dl .
    • Total Bilirubin < 1.5 times the upper limit of normal .
    • AST( aspartate aminotransferase), ALT (alanine aminotransferase)<2.5 times the upper limit of normal in patients without evidence of liver metastases.
    • AST, ALT <2.5 times the upper limit of normal in patients with evidence of liver metastases.
    • Alkaline phosphatase <2.5 times the upper limit of normal in patients with evidence of hepatic metastases
    • Values of serum creatinine < 1.5 mg / dl. - CCr ( Creatinine Clearance rate) ≥ 60 mL / min 9 . During the study of male and female patients must use adequate contraceptive methods .

Exclusion Criteria:

  1. Patients with histological evidence of malignant insulinoma ( pNET )
  2. Surgeries performed within 28 days prior to the start of treatment.
  3. Evidence of metastasis at the level of the central nervous system or spinal cord compression . Patients should be subjected to a recent study MRI or CT scan at least 28 days from the date of randomization.
  4. Clinically significant cardiovascular disease , such as cardiovascular accidents occurred in less than 6 months, unstable angina , congestive heart failure grade greater than or equal to II according to the classification of the New York Heart Association (NYHA) series cardiac arrhythmias that require treatment.
  5. Important comorbidities , metabolic disorders , clinical examination or laboratory investigations , which contraindicate the use of drugs to study, or patients at high risk of complications from the treatment.
  6. Active or uncontrolled severe infections .
  7. Cirrhosis , acute hepatitis or chronic active hepatitis .
  8. Poor control of diabetes HbA1c > = 8.0 % .
  9. Diabetic patients who are treated with metformin are eligible if they have enabled the treatment with metformin for less than 6 months. Are excluded diabetic patients who make use of other hypoglycemic agents such as sulfonylureas, insulin , glinides as monotherapy or in combination with metformin.
  10. Using anti - IL6 (Interleukin 6) or IGF1 .
  11. Uncontrolled high blood pressure , atrial fibrillation .
  12. History of immunosuppression included positive HIV test .
  13. No previous or concomitant oncological pathology , except: basal cell skin cancer, in situ , as long as every other cancer patient diseasefree for at least 5 years.
  14. They excluded patients with a condition of metabolic acidosis , acute or chronic , including ketoacidosis .
  15. History of alcohol abuse , or habitual intake of alcohol (≥ 3 glasses of alcoholic drinks / day) sufficient to cause hepatotoxicity.
  16. Prolonged fasting .
  17. Severe states of dehydration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02294006


Contacts
Layout table for location contacts
Contact: Filippo De Braud, MD segreteria.oncologiamedica@istitutotumori.mi.it
Contact: Sara Pusceddu, MD sara.pusceddu@istitutotumori.mi.it

Locations
Layout table for location information
Italy
Fondazione IRCCS Istituto Tumori Milano Recruiting
Milano, Italy, 20133
Contact: Sara Pusceddu, MD       sara.pusceddu@istitutotumori.mi.it   
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Investigators
Layout table for investigator information
Principal Investigator: Filippo De Braud, MD INT MILANO
Principal Investigator: Roberto Buzzoni, MD INT MILANO
Principal Investigator: Sara Pusceddu, MD INT MILANO

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier: NCT02294006     History of Changes
Other Study ID Numbers: Ist Nazionale Tumori Milano
First Posted: November 19, 2014    Key Record Dates
Last Update Posted: November 19, 2014
Last Verified: November 2014

Keywords provided by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano:
pancreatic
neuroendocrine
everolimus
metformin
octreotide

Additional relevant MeSH terms:
Layout table for MeSH terms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pancreatic Neoplasms
Digestive System Neoplasms
Adenoma, Islet Cell
Endocrine System Diseases
Adenoma
Digestive System Diseases
Pancreatic Diseases
Metformin
Everolimus
Sirolimus
Octreotide
Hypoglycemic Agents
Physiological Effects of Drugs
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Gastrointestinal Agents
Antineoplastic Agents, Hormonal